# PharmaCyte  Biotech Inc. (PMCB)

Source: https://www.quantisnow.com/company/PMCB
Generated: 2026-11-09T10:21:10.904Z

- Ticker: PMCB
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Biological Products (No Diagnostic Substances)
- SEC CIK: 0001157075
- Website: pharmacyte.com

## About

PharmaCyte Biotech, Inc., a biotechnology company, focuses on developing and commercializing cellular therapies for cancer and diabetes in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable non-metastatic pancreatic cancer, as well as diabetes. The company is developing therapies for pancreatic and other tumors, including encapsulated genetically modified living cells. It is also developing a therapy for Type 1 diabetes and insulin-dependent Type 2 diabetes; and therapies for cancer based on the constituents of the cannabis plant. The company has a research agreement with the University of Technology, Sydney to create a version of melligen cells to treat diabetes; and the University of Northern Colorado to develop methods for the identification, separation, and quantification of constituents of cannabis. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was incorporated in 1996 and is based in Laguna Hills, California.

## Latest PMCB news and filings

- 2026-10-16 21:00 UTC [SEC Form 8-K] [SEC Form 8-K filed by PharmaCyte  Biotech Inc.](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-pharmacyte-biotech-inc-6749450)
- 2026-09-14 20:05 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by PharmaCyte  Biotech Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-pharmacyte-biotech-inc-6714437)
- 2026-07-29 20:58 UTC [SEC Form 10-K] [SEC Form 10-K filed by PharmaCyte  Biotech Inc.](https://www.quantisnow.com/insight/sec-form-10-k-filed-by-pharmacyte-biotech-inc-6654190)
- 2026-07-17 21:00 UTC [SEC Form 4] [Amendment: SEC Form 4 filed by Director Weinstein Robert](https://www.quantisnow.com/insight/amendment-sec-form-4-filed-by-director-weinstein-robert-6641319)
- 2026-07-17 21:00 UTC [SEC Form 4] [Amendment: SEC Form 4 filed by Director Walker Wayne Remell](https://www.quantisnow.com/insight/amendment-sec-form-4-filed-by-director-walker-wayne-remell-6641316)
- 2026-07-17 21:00 UTC [SEC Form 4] [Amendment: SEC Form 4 filed by Director Abecassis Michael M](https://www.quantisnow.com/insight/amendment-sec-form-4-filed-by-director-abecassis-michael-m-6641315)
- 2026-07-17 21:00 UTC [SEC Form 4] [Amendment: SEC Form 4 filed by Director Schechter Jonathan](https://www.quantisnow.com/insight/amendment-sec-form-4-filed-by-director-schechter-jonathan-6641314)
- 2026-04-02 22:17 UTC [SEC Form 4] [SEC Form 4 filed by Walker Wayne Remell](https://www.quantisnow.com/insight/sec-form-4-filed-by-walker-wayne-remell-6486150)
- 2026-04-02 22:17 UTC [SEC Form 4] [SEC Form 4 filed by Weinstein Robert](https://www.quantisnow.com/insight/sec-form-4-filed-by-weinstein-robert-6486149)
- 2026-04-02 22:17 UTC [SEC Form 4] [SEC Form 4 filed by Schechter Jonathan](https://www.quantisnow.com/insight/sec-form-4-filed-by-schechter-jonathan-6486147)
- 2026-04-02 22:16 UTC [SEC Form 4] [SEC Form 4 filed by Abecassis Michael M](https://www.quantisnow.com/insight/sec-form-4-filed-by-abecassis-michael-m-6486145)
- 2026-04-02 20:19 UTC [SEC Form 8-K] [PharmaCyte  Biotech Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits](https://www.quantisnow.com/insight/pharmacyte-biotech-inc-filed-sec-form-8-k-leadership-update-submission-6484903)
- 2026-03-17 19:49 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by PharmaCyte  Biotech Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-pharmacyte-biotech-inc-6452150)
- 2026-03-09 10:02 UTC [SEC Form DEF 14A] [SEC Form DEF 14A filed by PharmaCyte  Biotech Inc.](https://www.quantisnow.com/insight/sec-form-def-14a-filed-by-pharmacyte-biotech-inc-6436064)
- 2026-02-27 22:05 UTC [SEC Form PRE 14A] [SEC Form PRE 14A filed by PharmaCyte  Biotech Inc.](https://www.quantisnow.com/insight/sec-form-pre-14a-filed-by-pharmacyte-biotech-inc-6419797)
- 2026-01-07 22:43 UTC [Insider Buy] [CEO and President Silverman Joshua bought $80,476 worth of shares (100,000 units at $0.80), increasing direct ownership by 32% to 416,250 units (SEC Form 4)](https://www.quantisnow.com/insight/ceo-and-president-silverman-joshua-bought-80476-worth-of-shares-6341686)
- 2026-01-07 22:43 UTC [Insider Buy] [Director Schechter Jonathan bought $48,232 worth of shares (60,000 units at $0.80), increasing direct ownership by 45% to 192,500 units (SEC Form 4)](https://www.quantisnow.com/insight/director-schechter-jonathan-bought-48232-worth-of-shares-60000-units-6341685)
- 2025-12-18 22:04 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by PharmaCyte  Biotech Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-pharmacyte-biotech-inc-6322535)
- 2025-12-15 21:00 UTC [SEC Form NT 10-Q filed by PharmaCyte  Biotech Inc.](https://www.quantisnow.com/insight/sec-form-nt-10-q-filed-by-pharmacyte-biotech-inc-6315882)
- 2025-12-12 22:08 UTC [SEC Form 4] [Director Weinstein Robert was granted 75,000 shares and covered exercise/tax liability with 33,750 shares (SEC Form 4)](https://www.quantisnow.com/insight/director-weinstein-robert-was-granted-75000-shares-and-covered-exercisetax-6314621)
- 2025-12-12 22:07 UTC [SEC Form 4] [Director Walker Wayne Remell covered exercise/tax liability with 16,875 shares and was granted 37,500 shares (SEC Form 4)](https://www.quantisnow.com/insight/director-walker-wayne-remell-covered-exercisetax-liability-with-16875-shares-6314620)
- 2025-12-12 22:07 UTC [SEC Form 4] [CEO and President Silverman Joshua was granted 575,000 shares and covered exercise/tax liability with 258,750 shares (SEC Form 4)](https://www.quantisnow.com/insight/ceo-and-president-silverman-joshua-was-granted-575000-shares-and-6314619)
- 2025-12-12 22:07 UTC [SEC Form 4] [Director Schechter Jonathan was granted 150,000 shares and covered exercise/tax liability with 67,500 shares, increasing direct ownership by 165% to 132,500 units (SEC Form 4)](https://www.quantisnow.com/insight/director-schechter-jonathan-was-granted-150000-shares-and-covered-exercisetax-6314616)
- 2025-12-12 22:06 UTC [SEC Form 4] [Director Abecassis Michael M was granted 37,500 shares and covered exercise/tax liability with 16,875 shares, increasing direct ownership by 1,237% to 22,292 units (SEC Form 4)](https://www.quantisnow.com/insight/director-abecassis-michael-m-was-granted-37500-shares-and-covered-6314615)
- 2025-12-05 22:00 UTC [SEC Form 8-K] [SEC Form 8-K filed by PharmaCyte  Biotech Inc.](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-pharmacyte-biotech-inc-6305391)
- 2025-11-25 14:15 UTC [PharmaCyte Biotech Successfully Monetizes Femasys Stake, Strengthening Cash Position and Underscoring Strategic Capital Deployment](https://www.quantisnow.com/insight/pharmacyte-biotech-successfully-monetizes-femasys-stake-strengthening-cash-position-and-6293089)
- 2025-11-18 21:05 UTC [SEC Form 8-K] [Amendment: PharmaCyte  Biotech Inc. filed SEC Form 8-K: Financial Statements and Exhibits](https://www.quantisnow.com/insight/amendment-pharmacyte-biotech-inc-filed-sec-form-8-k-financial-statements-6284835)
- 2025-10-31 20:05 UTC [SEC Form 8-K] [PharmaCyte  Biotech Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits](https://www.quantisnow.com/insight/pharmacyte-biotech-inc-filed-sec-form-8-k-leadership-update-submission-6254473)
- 2025-10-06 21:08 UTC [SEC Form DEF 14A] [SEC Form DEF 14A filed by PharmaCyte  Biotech Inc.](https://www.quantisnow.com/insight/sec-form-def-14a-filed-by-pharmacyte-biotech-inc-6224955)
- 2025-09-29 04:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by PharmaCyte  Biotech Inc.](https://www.quantisnow.com/insight/sec-form-effect-filed-by-pharmacyte-biotech-inc-6213648)
- 2025-09-24 20:32 UTC [SEC Form PRE 14A] [SEC Form PRE 14A filed by PharmaCyte  Biotech Inc.](https://www.quantisnow.com/insight/sec-form-pre-14a-filed-by-pharmacyte-biotech-inc-6210763)
- 2025-09-15 20:37 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by PharmaCyte  Biotech Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-pharmacyte-biotech-inc-6201176)
- 2025-09-05 20:05 UTC [SEC Form 8-K] [PharmaCyte  Biotech Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/pharmacyte-biotech-inc-filed-sec-form-8-k-entry-into-a-6191631)
- 2025-09-04 01:37 UTC [SEC Form D] [SEC Form D filed by PharmaCyte  Biotech Inc.](https://www.quantisnow.com/insight/sec-form-d-filed-by-pharmacyte-biotech-inc-6189073)
- 2025-09-02 13:20 UTC [PharmaCyte Biotech, Inc. Increases Stake in TNF Pharmaceuticals Around Recent License for Breakthrough Light Speed Computing Platform for Use in Cryptocurrency Applications](https://www.quantisnow.com/insight/pharmacyte-biotech-inc-increases-stake-in-tnf-pharmaceuticals-around-recent-6185323)
- 2025-08-20 13:15 UTC [Public Offering] [PharmaCyte Biotech, Inc. Announces Closing of $7 Million Financing](https://www.quantisnow.com/insight/pharmacyte-biotech-inc-announces-closing-of-7-million-financing-6173095)
- 2025-08-18 13:20 UTC [SEC Form 8-K] [PharmaCyte  Biotech Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/pharmacyte-biotech-inc-filed-sec-form-8-k-entry-into-a-6169627)
- 2025-08-18 13:15 UTC [Public Offering] [PharmaCyte Biotech, Inc. Announces $7 Million Capital Raise Led by Existing Investors](https://www.quantisnow.com/insight/pharmacyte-biotech-inc-announces-7-million-capital-raise-led-by-6169618)
- 2025-07-29 21:26 UTC [SEC Form NT 10-K filed by PharmaCyte  Biotech Inc.](https://www.quantisnow.com/insight/sec-form-nt-10-k-filed-by-pharmacyte-biotech-inc-6137092)
- 2025-04-24 20:47 UTC [SEC Form 8-K] [PharmaCyte  Biotech Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders](https://www.quantisnow.com/insight/pharmacyte-biotech-inc-filed-sec-form-8-k-submission-of-matters-6001126)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/PMCB
- Earnings history: https://www.quantisnow.com/earnings/PMCB
- Dividend history: https://www.quantisnow.com/dividends/PMCB
- Insider transactions: https://www.quantisnow.com/insiders/PMCB
- Options chain: https://www.quantisnow.com/options/PMCB
- SEC 8-K filings only: https://www.quantisnow.com/company/PMCB/8-k
- RSS and alerts for PMCB: https://www.quantisnow.com/docs/rss-feeds.md